These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

716 related articles for article (PubMed ID: 26354054)

  • 1. Oral udenafil and aceclofenac for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a randomized multicenter study.
    Lee TY; Choi JS; Oh HC; Song TJ; Do JH; Cheon YK
    Korean J Intern Med; 2015 Sep; 30(5):602-9. PubMed ID: 26354054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of udenafil is not associated with a reduction in post-ERCP pancreatitis: results of a randomized, placebo-controlled, multicenter trial.
    Oh HC; Cheon YK; Cho YD; Do JH
    Gastrointest Endosc; 2011 Sep; 74(3):556-62. PubMed ID: 21802079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No Benefit of Oral Diclofenac on Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis.
    Ishiwatari H; Urata T; Yasuda I; Matsusaki S; Hisai H; Kawakami H; Ono M; Iwashita T; Doi S; Kawakubo K; Hayashi T; Sonoda T; Sakamoto N; Kato J
    Dig Dis Sci; 2016 Nov; 61(11):3292-3301. PubMed ID: 27447477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of diclofenac plus somatostatin in the prevention of post-ERCP pancreatitis: a randomized, double-blind, placebo-controlled trial.
    Katsinelos P; Fasoulas K; Paroutoglou G; Chatzimavroudis G; Beltsis A; Terzoudis S; Katsinelos T; Dimou E; Zavos C; Kaltsa A; Kountouras J
    Endoscopy; 2012 Jan; 44(1):53-9. PubMed ID: 22198776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppository naproxen reduces incidence and severity of post-endoscopic retrograde cholangiopancreatography pancreatitis: Randomized controlled trial.
    Mansour-Ghanaei F; Joukar F; Taherzadeh Z; Sokhanvar H; Hasandokht T
    World J Gastroenterol; 2016 Jun; 22(21):5114-21. PubMed ID: 27275104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of rectal indomethacin, diclofenac, and naproxen for the prevention of post endoscopic retrograde cholangiopancreatography pancreatitis.
    Mohammad Alizadeh AH; Abbasinazari M; Hatami B; Abdi S; Ahmadpour F; Dabir S; Nematollahi A; Fatehi S; Pourhoseingholi MA
    Eur J Gastroenterol Hepatol; 2017 Mar; 29(3):349-354. PubMed ID: 27849643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rectal Diclofenac administration for prevention of post-Endoscopic Retrograde Cholangio-Pancreatography (ERCP) acute pancreatitis. Randomized prospective study.
    Geraci G; Palumbo VD; D'Orazio B; Maffongelli A; Fazzotta S; Lo Monte AI
    Clin Ter; 2019; 170(5):e332-e336. PubMed ID: 31612188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for post-ERCP pancreatitis: a prospective multicenter study.
    Cheng CL; Sherman S; Watkins JL; Barnett J; Freeman M; Geenen J; Ryan M; Parker H; Frakes JT; Fogel EL; Silverman WB; Dua KS; Aliperti G; Yakshe P; Uzer M; Jones W; Goff J; Lazzell-Pannell L; Rashdan A; Temkit M; Lehman GA
    Am J Gastroenterol; 2006 Jan; 101(1):139-47. PubMed ID: 16405547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diclofenac sodium versus ceftazidime for preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a prospective, randomized, controlled trial.
    Hauser G; Blažević I; Salkić N; Poropat G; Giljača V; Bulić Z; Štimac D
    Surg Endosc; 2017 Feb; 31(2):602-610. PubMed ID: 27317032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-ERCP pancreatitis.
    Arata S; Takada T; Hirata K; Yoshida M; Mayumi T; Hirota M; Yokoe M; Hirota M; Kiriyama S; Sekimoto M; Amano H; Wada K; Kimura Y; Gabata T; Takeda K; Kataoka K; Ito T; Tanaka M
    J Hepatobiliary Pancreat Sci; 2010 Jan; 17(1):70-8. PubMed ID: 20012323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rectal diclofenac does not prevent post-ERCP pancreatitis in consecutive high-risk and low-risk patients.
    Del Olmo Martínez L; Velayos Jiménez B; Almaraz Gómez A
    Rev Esp Enferm Dig; 2018 Aug; 110(8):505-509. PubMed ID: 29667415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prophylactic effect of somatostatin on post-therapeutic endoscopic retrograde cholangiopancreatography pancreatitis: a randomized, multicenter controlled trial.
    Lee KT; Lee DH; Yoo BM
    Pancreas; 2008 Nov; 37(4):445-8. PubMed ID: 18953260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intramuscular diclofenac for the prevention of post-ERCP pancreatitis: a randomized trial.
    Park SW; Chung MJ; Oh TG; Park JY; Bang S; Park SW; Song SY
    Endoscopy; 2015 Jan; 47(1):33-9. PubMed ID: 25409167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rectal indomethacin versus placebo to reduce the incidence of pancreatitis after endoscopic retrograde cholangiopancreatography: results of a controlled clinical trial.
    Andrade-Dávila VF; Chávez-Tostado M; Dávalos-Cobián C; García-Correa J; Montaño-Loza A; Fuentes-Orozco C; Macías-Amezcua MD; García-Rentería J; Rendón-Félix J; Cortés-Lares JA; Ambriz-González G; Cortés-Flores AO; Alvarez-Villaseñor Adel S; González-Ojeda A
    BMC Gastroenterol; 2015 Jul; 15():85. PubMed ID: 26195123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of diclofenac in the prevention of post-ERCP pancreatitis in predominantly high-risk patients: a randomized double-blind prospective trial.
    Cheon YK; Cho KB; Watkins JL; McHenry L; Fogel EL; Sherman S; Schmidt S; Lazzell-Pannell L; Lehman GA
    Gastrointest Endosc; 2007 Dec; 66(6):1126-32. PubMed ID: 18061712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nasobiliary drainage can reduce the incidence of post-ERCP pancreatitis after papillary large balloon dilation plus endoscopic biliary sphincterotomy: a randomized controlled trial.
    Huang Q; Shao F; Wang C; Qi W; Qiu LJ; Liu Z
    Scand J Gastroenterol; 2018 Jan; 53(1):114-119. PubMed ID: 29043861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is impact of nonsteroidal anti-inflammatory drugs in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis of randomized controlled trials.
    Lyu Y; Cheng Y; Wang B; Xu Y; Du W
    BMC Gastroenterol; 2018 Jul; 18(1):106. PubMed ID: 29973142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial.
    Andriulli A; Clemente R; Solmi L; Terruzzi V; Suriani R; Sigillito A; Leandro G; Leo P; De Maio G; Perri F
    Gastrointest Endosc; 2002 Oct; 56(4):488-95. PubMed ID: 12297762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effectiveness of the Rectal Administration of Low-dose Diclofenac for the Prevention of Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis.
    Okuno M; Shiroko J; Taguchi D; Yamaguchi K; Takada J; Imai S; Sato H; Thanabashi S
    Intern Med; 2018 Aug; 57(16):2289-2294. PubMed ID: 29607957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylaxis of pancreatitis with intravenous ketoprofen in a consecutive population of ERCP patients: a randomized double-blind placebo-controlled trial.
    de Quadros Onófrio F; Lima JCP; Watte G; Lehmen RL; Oba D; Camargo G; Dos Santos CEO
    Surg Endosc; 2017 May; 31(5):2317-2324. PubMed ID: 27651353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.